398 related articles for article (PubMed ID: 32454289)
1. The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment.
Liu Y; Ju M; Wang Z; Li J; Shao C; Fu T; Jing Y; Zhao Y; Lv Z; Li G
Biomed Pharmacother; 2020 Aug; 128():110235. PubMed ID: 32454289
[TBL] [Abstract][Full Text] [Related]
2. Modification of COL1A1 in Autologous Adipose Tissue-Derived Progenitor Cells Rescues the Bone Phenotype in a Mouse Model of Osteogenesis Imperfecta.
Liu Y; Wang Z; Ju M; Zhao Y; Jing Y; Li J; Shao C; Fu T; Lv Z; Li G
J Bone Miner Res; 2021 Aug; 36(8):1521-1534. PubMed ID: 33950576
[TBL] [Abstract][Full Text] [Related]
3. DNA methyltransferases inhibitor azacitidine improves the skeletal phenotype of mild osteogenesis imperfecta by reversing the impaired osteogenesis and excessive osteoclastogenesis.
Shao C; Liu Y; Zhao Y; Jing Y; Li J; Lv Z; Fu T; Wang Z; Li G
Bone; 2023 May; 170():116706. PubMed ID: 36822490
[TBL] [Abstract][Full Text] [Related]
4. NEL-Like Molecule-1 (Nell1) Is Regulated by Bone Morphogenetic Protein 9 (BMP9) and Potentiates BMP9-Induced Osteogenic Differentiation at the Expense of Adipogenesis in Mesenchymal Stem Cells.
Wang J; Liao J; Zhang F; Song D; Lu M; Liu J; Wei Q; Tang S; Liu H; Fan J; Zou Y; Guo D; Huang J; Liu F; Ma C; Hu X; Li L; Qu X; Chen L; Weng Y; Lee MJ; He TC; Reid RR; Zhang J
Cell Physiol Biochem; 2017; 41(2):484-500. PubMed ID: 28214873
[TBL] [Abstract][Full Text] [Related]
5. A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I.
Liu Y; Wang J; Liu S; Kuang M; Jing Y; Zhao Y; Wang Z; Li G
Bone; 2019 Oct; 127():646-655. PubMed ID: 31369917
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of osteogenesis in iPSC-derived mesenchymal stem cells from osteogenesis imperfecta patients by endoplasmic reticulum stress inhibitor.
Duangchan T; Tawonsawatruk T; Angsanuntsukh C; Trachoo O; Hongeng S; Kitiyanant N; Supokawej A
Life Sci; 2021 Aug; 278():119628. PubMed ID: 34015290
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
[TBL] [Abstract][Full Text] [Related]
8. Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta.
Infante A; Alcorta-Sevillano N; Macías I; Cabodevilla L; Medhat D; Lafaver B; Crawford TK; Phillips CL; Bueno AM; Sagastizabal B; Arroyo M; Campino A; Gerovska D; Araúzo-Bravo M; Gener B; Rodríguez CI
Biomed Pharmacother; 2024 Jun; 175():116725. PubMed ID: 38744219
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of TAZ enhances osteogenic differentiation and bone formation of adipose-derived stem cells.
Zhu Y; Wu Y; Cheng J; Wang Q; Li Z; Wang Y; Wang D; Wang H; Zhang W; Ye J; Jiang H; Wang L
Stem Cell Res Ther; 2018 Mar; 9(1):53. PubMed ID: 29514703
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of bone marrow mesenchymal stem cells from Osteogenesis Imperfecta patients during osteoblast differentiation.
Kaneto CM; Pereira Lima PS; Prata KL; Dos Santos JL; de Pina Neto JM; Panepucci RA; Noushmehr H; Covas DT; de Paula FJA; Silva WA
Eur J Med Genet; 2017 Jun; 60(6):326-334. PubMed ID: 28396251
[TBL] [Abstract][Full Text] [Related]
11. Osteogenic differentiation of human periodontal ligament stem cells expressing lentiviral NEL-like protein 1.
Chen CY; Liu YJ; Shi SG; Chen FM; Cai C; Li B; Wang J; Shi L; Li Y; Liu ZY; Niu ZY
Int J Mol Med; 2012 Oct; 30(4):863-9. PubMed ID: 22767336
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of MiR-140-5 promotes osteogenesis of adipose-derived mesenchymal stem cells by targeting TLR4 and BMP2 and promoting fracture healing in the atrophic nonunion rat model.
Guo PY; Wu LF; Xiao ZY; Huang TL; Li X
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2112-2124. PubMed ID: 30915756
[TBL] [Abstract][Full Text] [Related]
13. NELL1 promotes high-quality bone regeneration in rat femoral distraction osteogenesis model.
Xue J; Peng J; Yuan M; Wang A; Zhang L; Liu S; Fan M; Wang Y; Xu W; Ting K; Zhang X; Lu S
Bone; 2011 Mar; 48(3):485-95. PubMed ID: 20959151
[TBL] [Abstract][Full Text] [Related]
14. Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement.
Liu J; Chen W; Zhao Z; Xu HHK
Acta Biomater; 2014 Dec; 10(12):5128-5138. PubMed ID: 25220281
[TBL] [Abstract][Full Text] [Related]
15. Solanum muricatum Ameliorates the Symptoms of Osteogenesis Imperfecta In Vivo.
Wang N; Wang L; Wang Z; Cheng L; Wang J
J Food Sci; 2019 Jun; 84(6):1646-1650. PubMed ID: 31116433
[TBL] [Abstract][Full Text] [Related]
16. Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial.
Infante A; Gener B; Vázquez M; Olivares N; Arrieta A; Grau G; Llano I; Madero L; Bueno AM; Sagastizabal B; Gerovska D; Araúzo-Bravo MJ; Astigarraga I; Rodríguez CI
Clin Transl Med; 2021 Jan; 11(1):e265. PubMed ID: 33463067
[TBL] [Abstract][Full Text] [Related]
17. Repair of bone defects in rat radii with a composite of allogeneic adipose-derived stem cells and heterogeneous deproteinized bone.
Liu J; Zhou P; Long Y; Huang C; Chen D
Stem Cell Res Ther; 2018 Mar; 9(1):79. PubMed ID: 29587852
[TBL] [Abstract][Full Text] [Related]
18. Time-Phase Sequential Utilization of Adipose-Derived Mesenchymal Stem Cells on Mesoporous Bioactive Glass for Restoration of Critical Size Bone Defects.
Du J; Xie P; Lin S; Wu Y; Zeng D; Li Y; Jiang X
ACS Appl Mater Interfaces; 2018 Aug; 10(34):28340-28350. PubMed ID: 30080385
[TBL] [Abstract][Full Text] [Related]
19. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
[TBL] [Abstract][Full Text] [Related]
20. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
